Trials / NCT04604899
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
Completed Phase 2 Cell therapy
- Sponsor
- jCyte, Inc
- Treatment
- human retinal progenitor cells
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 30 participants
- Started
- 2020-12-01
- Main results expected
- 2022-03-22
- Results posted
- Yes
- Record last updated
- 2024-07-16
What the study is testing
The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.
Where it runs
United States (3)
- Gavin Herbert Eye Inst, Univ Cal Irvine, Irvine, California
- Retina-Vitreous Associates Medical Group, Los Angeles, California
- Ophthalmic Consultants of Boston, Boston, Massachusetts